News | October 29, 2009

Thermo Fisher Scientific Launches New AMI Biomarker Test in Europe

October 28, 2009 – Thermo Fisher Scientific Inc. today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI).

Copeptin, developed by recently acquired B.R.A.H.M.S. AG, is a patented biomarker for AMI and is detectable using a simple blood test that, in combination with a Troponin biomarker test, permits doctors to rule out or confirm the onset of a heart attack within minutes. Currently, physicians rely on an electrocardiogram in combination with Troponin which, in most patients with chest pain, cannot indicate AMI until at least four hours after the onset of symptoms and requires additional testing after six to nine hours.

“We acquired B.R.A.H.M.S. to strengthen our specialty diagnostics offering, and today’s news demonstrates how quickly that investment is adding value to our technology portfolio,” said Yuh-Geng Tsay, Ph.D., head of Thermo Fisher Scientific’s specialty diagnostics business. “Our company continues to push innovation in biomarker discovery and applications. The Copeptin assay shows that we’re having an impact by helping physicians to be more effective at diagnosing disease, which ultimately improves patient health and also lowers the cost of care.”

AMI is the leading cause of death worldwide. Approximately 15 million patients visit an emergency room each year with symptoms, however, only about 10 percent are eventually diagnosed with AMI. The Copeptin assay allows physicians to provide immediate answers. It accelerates treatment, prevents heart damage caused by prolonged wait time and streamlines the treatment of non-AMI patients. Copeptin can save valuable time, healthcare resources and, most importantly, human lives.

The test is now commercially available throughout Europe. In the U.S., Thermo Fisher is in the process of generating the data to support a 510(k) premarket application for the test, and plans to submit the data to the U.S. Food and Drug Administration at the end of 2010.

Thermo Fisher Scientific completed the acquisition of B.R.A.H.M.S. on Oct. 1, 2009.

For more information: www.thermofisher.com

Related Content

NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
PURE study may cause revision of fat intake guidelines for cardiology.
Feature | ESC| September 07, 2017
September 7, 2017 — Researchers at the European Society of Cardiology (ESC) Congress called for a reconsideration of
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Advances in FFR, FFR-CT, was the most popular cardiology story in August 2017.

The most popular article in August was about advances in fractional flow reserve (FFR) technologies. The image shows Philips' new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions.

Feature | September 01, 2017 | Dave Fornell
September 1, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Car
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Overlay Init